V
64
-4
ORLY
64
2
QRVO
33
-3
PCG
74
-6
FTI
69
-7
EA
44
-2
AN
49
2
ES
55
-5
ABBV
51
-2
HSIC
56
3
MSI
69
-3
SWK
80
2
TGT
50
2
HON
55
-4
KLAC
56
-3
CMCSA
52
6
NRG
57
2
VNO
59
3
AEP
59
-3
ETR
68
-3
V
64
-4
ORLY
64
2
QRVO
33
-3
PCG
74
-6
FTI
69
-7
EA
44
-2
AN
49
2
ES
55
-5
ABBV
51
-2
HSIC
56
3
MSI
69
-3
SWK
80
2
TGT
50
2
HON
55
-4
KLAC
56
-3
CMCSA
52
6
NRG
57
2
VNO
59
3
AEP
59
-3
ETR
68
-3
Financhill
Back

Y-mAbs Therapeutics Quote, Financials, Valuation and Earnings

Hedge fund manager warns about the market ahead

Free book prepares you for the coming uncertainty in the stock market
Buy
59

YMAB
Y-mAbs Therapeutics

Last Price:
14.00
Seasonality Move:
-10.6%

7 Day Trial

ALL ACCESS PASS

$ 7

The Next Tech Giant in Your Pocket?

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.

Y-mAbs Therapeutics Price Quote

$14.00
+0.43 (+3.17%)
(Updated: September 19, 2024 at 6:55 PM ET)

Y-mAbs Therapeutics Key Stats

Buy
59
Y-mAbs Therapeutics (YMAB) is a Buy
Day range:
$13.50 - $14.42
52-week range:
$4.69 - $20.90
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
6.86
P/B ratio:
6.34%
Volume:
321.1K
Avg. volume:
304K
1-year change:
167.65%
Market cap:
$604.8M
Revenue:
$84.8M
EPS:
$-0.56

How Much Does Y-mAbs Therapeutics Make?

Is Y-mAbs Therapeutics Growing As A Company?

  • What Is Y-mAbs Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.1%
  • What Is Y-mAbs Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Y-mAbs Therapeutics Stock Price Performance

What Is Y-mAbs Therapeutics 52-Week High & Low?

Y-mAbs Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Y-mAbs Therapeutics?

Is Y-mAbs Therapeutics Cash Flow Positive?

  • What Is YMAB Cash Flow From Operations?
    Cash flow from operations (TTM) is -$12.6M
  • What Is Y-mAbs Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $2.4M
  • What Is Y-mAbs Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $0

Y-mAbs Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    YMAB return on invested capital is -24.6%
  • What Is Y-mAbs Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -18.75%
  • What Is YMAB Return On Equity?
    ROE is a measure of profitability and is -24.6%

Y-mAbs Therapeutics Earnings Date & Stock Price

Y-mAbs Therapeutics Competitors

Y-mAbs Therapeutics Dividend Yield

Y-mAbs Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -77.47%
Revenue: 9.87% -0.96%

Analyst Recommendations

Buy Recommendations: 5
Hold Recommendations: 1
Sell Recommendations: 1
Price Target: 20.89
Upside from Last Price: 53.93%

Major Shareholders

  • How many YMAB shares are owned by institutional investors?
    36.8M YMAB shares are owned by institutional investors
  • How many YMAB shares are owned by insiders?
    851.2K YMAB shares are owned by insiders